Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-23T05:18:59.075Z Has data issue: false hasContentIssue false
  • English
  • Français

REPORT FROM THE UNIVERSITY HEALTHSYSTEM CONSORTIUM

Published online by Cambridge University Press:  01 May 1999

Get access Rights & Permissions [Opens in a new window]

Abstract

Recombinant human erythropoietin (Epo) use represents a substantial pharmaceutical expense for UHC hospital members. In 1997 it ranked second to filgrastim (G-CSF), with UHC member annual purchases totaling more than $23 million.

Type
TECHNOLOGY ASSESSMENT REPORTS
Information
International Journal of Technology Assessment in Health Care , Volume 15 , Issue 2 , May 1999 , pp. 424 - 438
Copyright
© 1999 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)